Compare USLM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | ZLAB |
|---|---|---|
| Founded | 1948 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.6B |
| IPO Year | 1994 | 2017 |
| Metric | USLM | ZLAB |
|---|---|---|
| Price | $111.80 | $25.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $138.00 | $49.60 |
| AVG Volume (30 Days) | 106.2K | ★ 766.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | 23.22 | ★ 38.46 |
| EPS | ★ 2.26 | N/A |
| Revenue | $144,435,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $27.25 | $9.75 |
| Revenue Next Year | $13.76 | $26.03 |
| P/E Ratio | $48.42 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $96.27 | $15.96 |
| 52 Week High | $141.44 | $34.72 |
| Indicator | USLM | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 49.96 |
| Support Level | $102.60 | $24.81 |
| Resistance Level | $114.22 | $25.28 |
| Average True Range (ATR) | 3.08 | 0.77 |
| MACD | -0.79 | -0.14 |
| Stochastic Oscillator | 41.60 | 41.43 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. The company supplies its products predominantly to the construction including highway, road, and building contractors, industrial including paper and glass manufacturers, environmental including municipal sanitation and water treatment facilities and flue gas treatment processes, metals including steel producers, oil and gas services, roof shingle manufacturers and agriculture including poultry industries. The company operates through its Lime and Limestone Operations segment.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.